Furthermore, addition of Ras-effector inhibitor therapies are believed to enhance the effects of tipifarnib, through reduction of compensatory MAPK/PI3K pathway signalling potentially brought about by HRAS inhibition in head and neck cancer cell lines (Javaid et al., 2022). Here, HRAS is linked to head and neck cancer.